Breast Cancer Clinical Trial
Official title:
Pre-Surgical Qigong Therapy for Women With Breast Cancer
| NCT number | NCT00495209 |
| Other study ID # | 2005-0876 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | July 26, 2006 |
| Est. completion date | March 7, 2018 |
| Verified date | August 2018 |
| Source | M.D. Anderson Cancer Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The use of complementary and alternative medicine (CAM) in the United States has increased
dramatically in the past 10 years. Nowhere is this trend more apparent than when one examines
CAM use by patients diagnosed with cancer. As with the general population, patients with
cancer typically use CAM-based modalities alongside their conventional cancer treatments.
Patients are often seeking a holistic approach to managing and preventing disease. Although
most patients will combine alternative approaches with conventional medicine, some patients
do in fact decline curative conventional treatments in favor of more non-toxic alternative
approaches. One such approach that patients combine with conventional medicine or use in
place of conventional medicine is qigong.
Qigong is a bioenergy therapy with a long history of therapeutic use for many diseases,
including cancer. Preliminary experiments and a review of the literature show that qigong
might improve the outcome for cancer patients. However, none of this research has been
confirmed in the peer-reviewed Western scientific literature. Although it is unlikely that
EQT will result in significant decreases in tumor size, patients are using qigong either as a
complementary approach, and sometimes even in place of conventional medicine, it is,
therefore, important for us to determine whether there is any merit to this treatment
modality. The goal of this pilot trial is to examine one form of medical qigong (external qi
therapy (EQT)) to determine feasibility. In an exploratory nature we will also examine any
changes in tumor size in women with breast cancer who are awaiting surgery.
| Status | Completed |
| Enrollment | 7 |
| Est. completion date | March 7, 2018 |
| Est. primary completion date | March 7, 2018 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: 1. Histologically confirmed and intact invasive ductal carcinoma 2. Women with a single measurable mass less than or equal to 3 cm 3. Women who are awaiting the surgical removal of breast cancer 4. Surgery is scheduled at least 2 weeks from the time of recruitment 5. Willing to come to MDACC or Fudan University Cancer Hospital (FUCH) for 5 consecutive days to receive the EQT 6. 18 years of age or older because the assessment tools are not validated for use in minors. Exclusion Criteria: 1. Women with lobular carcinoma 2. Prior or planned neoadjuvant treatment with chemotherapy or radiotherapy 3. Evidence of metastatic disease |
| Country | Name | City | State |
|---|---|---|---|
| United States | UT MD Anderson Cancer Center | Houston | Texas |
| Lead Sponsor | Collaborator |
|---|---|
| M.D. Anderson Cancer Center |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Feasibility of conducting external qigong in women with breast cancer awaiting surgery | 3 Years | ||
| Secondary | Initial efficacy of external qi therapy (EQT) as measured by tumor size | Baseline to end of treatment (5 days) |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |